Peptide Clinical Trials: Major Studies to Watch in 2026

Medical Disclaimer: This article describes ongoing and planned clinical research. None of the investigational peptides discussed here are FDA-approved for the indications mentioned unless explicitly stated. Clinical trial results may not translate to approved therapeutic uses. Do not use any medication or investigational compound without consulting a licensed healthcare provider.

Clinical trials represent the bridge between promising laboratory findings and regulated medical treatments. For peptide science, 2026 is a year of significant activity — several compounds that have been stuck in preclinical stages are advancing to human studies, while others that have completed early trials are moving toward larger efficacy studies. Here is a roundup of the most significant peptide trials to watch.

Wound Healing and Tissue Repair

Thymosin Beta-4 (TB-500 Fragment) — Phase 2 Corneal Healing

RegeneRx Biopharmaceuticals is advancing a Phase 2 trial of RGN-259, a thymosin beta-4 ophthalmic solution, for the treatment of neurotrophic keratopathy — a rare but serious corneal disease caused by impaired nerve function. Phase 1 results showed the treatment was well-tolerated with signals of efficacy in corneal healing.

This trial is significant because TB-500 and its synthetic analog are among the most widely used compounded peptides for injury recovery. If RGN-259 advances toward approval, it would represent the first FDA-approved thymosin beta-4 product, which may affect the compounding landscape for related preparations.

Synthetic BPC-157 Analog — Phase 1 GI Indications

A European biotech group filed a Phase 1 IND in late 2025 for a synthetic BPC-157 analog (modified for improved oral bioavailability) targeting inflammatory bowel disease. The trial is designed primarily to assess safety and pharmacokinetics. Enrollment is expected to begin in mid-2026 at sites in Germany and Croatia, where research interest in BPC-157 has been strongest.

This is notable because it represents the first controlled human trial of a BPC-157-class compound, though the synthetic analog differs from the preparations commonly compounded in the U.S.

Metabolic and Obesity Medicine

Retatrutide (GLP-1/GIP/Glucagon Triple Agonist) — Phase 3

Eli Lilly’s retatrutide, a triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously, has advanced to Phase 3 trials. Phase 2 data showed mean weight loss of approximately 24% at 48 weeks — exceeding single and dual agonist comparators. Phase 3 is evaluating cardiovascular outcomes and long-term weight maintenance.

Retatrutide is not a compounded peptide — it is a proprietary pharmaceutical — but its development matters to the consumer peptide space because it represents the continuing evolution of receptor agonist therapy beyond semaglutide and tirzepatide.

MOTS-c — Phase 1 (Pending IND Clearance)

Cohbar Inc. has an IND application in process with the FDA for a mitochondrial-derived peptide analog in metabolic syndrome. The compound is CB5945, which incorporates elements of the MOTS-c mechanism. No human dosing has occurred as of early 2026; Phase 1 initiation is contingent on IND clearance expected in mid-2026.

Longevity and Age-Related Conditions

Humanin Analogs — Phase 1 Safety Study

Humanin, another mitochondrial-derived peptide first characterized in the early 2000s, has shown effects on insulin sensitivity and neuroprotection in preclinical models. USC’s Leonard Davis School of Gerontology is conducting a Phase 1 study of a humanin analog (HNG) in healthy older adults to establish pharmacokinetics and safety. Preliminary results from the first cohort are expected to be presented at a geroscience conference in late 2026.

Epithalon — Observational Study (Russia/Europe)

Epithalon, a tetrapeptide derived from the pineal gland protein epithalamin, has a longer history in Eastern European longevity research but limited controlled trial data recognized by Western regulatory standards. A multicenter observational study involving 400 adults aged 60–80 began enrollment in 2025 at sites in Germany and the Czech Republic, examining biomarkers of aging, telomere length, and functional capacity over 24 months.

Neuropeptides and CNS Applications

Selank — Phase 2 Anxiety and Cognitive Function (Europe)

Selank, a synthetic analog of the endogenous neuropeptide tuftsin, has been used clinically in Russia and is now being evaluated in a Phase 2 European trial for generalized anxiety disorder and mild cognitive impairment. It is a Category 3 substance in the U.S. and cannot be legally compounded here, but European trial results may eventually influence a U.S. IND application.

PT-141 (Bremelanotide) — New Indications

PT-141, already FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, has ongoing investigator-initiated studies exploring use in male sexual dysfunction. These are not manufacturer-sponsored trials, but the compound’s Category 1 compounding status makes it particularly relevant to the telehealth and compounding pharmacy community.

What to Watch in the Coming Months

The most consequential trials for the consumer peptide space in the near term are:

1. TB-500/Thymosin Beta-4 Phase 2 results (RGN-259) — will influence compounding access
2. BPC-157 analog Phase 1 safety data — first controlled human data on this compound class
3. MOTS-c IND clearance — signals regulatory path for mitochondrial-derived peptides
4. Humanin analog Phase 1 results — first human data on this longevity peptide class

Informed Peptide will publish updates as trial data becomes available. Clinical trial recruitment listings can be found at ClinicalTrials.gov.

---

Sources: ClinicalTrials.gov (March 2026); NIH NCATS Peptide Drug Pipeline (2026); Alliance for Regenerative Medicine (2025); Journal of Clinical Investigation (2025). Information reflects publicly available trial data as of April 2026.